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Abstract: Exacerbations contribute significantly to the morbidity of COPD, leading to an 
accelerated decline in lung function, reduced functional status, reduced health status and qual-
ity of life, poorer prognosis and increased mortality. Prevention of exacerbations is thus an 
important goal of COPD management. In patients with COPD, treatment with a combination 
of the inhaled corticosteroid fluticasone propionate (250 µg) and the long-acting β2-agonist 
salmeterol (50 µg) in a single inhaler (250/50 µg) is an effective therapy option that has been 
shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health 
status, and to be relatively cost-effective as a COPD maintenance therapy. Importantly, results 
of various studies suggest that fluticasone propionate and salmeterol have synergistic effects 
when administered together that improve their efficacy in controlling symptoms and reducing 
exacerbations. The present non-systematic review summarizes the role of fluticasone propionate/
salmeterol combination therapy in the prevention of exacerbations of COPD and its related 
effects on lung function, survival, health status, and healthcare costs.
Keywords: Advair, COPD, disease exacerbation, fluticasone propionate, salmeterol, combina-
tion drug therapy
Introduction
Exacerbations contribute significantly to the morbidity, mortality and cost burden of 
COPD, a disease characterized by progressive air flow limitation that is not entirely 
reversible, airway inflammation and mucociliary dysfunction.1,2 In addition to produc-
ing short-term increases in breathlessness and other symptoms, exacerbations have 
sustained effects, including an accelerated decline in lung function,3,4 reduced health 
status and quality of life,5–9 and increased risk of death.10–11 Although therapeutic inter-
ventions to control the clinical symptoms of COPD and reduce airway inflammation 
are available, most studies indicate available treatments do not slow the long-term 
progression of the disease.2 However, newer therapies, including combination therapy 
with an inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA), are able to 
prevent episodes of exacerbation, thereby enhancing treatment strategies, particularly 
for moderate-to-severe COPD.
The present non-systematic review summarizes the role of fluticasone propionate 
and salmeterol combination therapy (FSC) in the prevention of exacerbations of COPD 
as well as its related effects on lung function, survival, health status and quality of life, 
and healthcare costs. This review also discusses prescribing considerations of interest 
to practicing clinicians. Although the intended focus of this review is FSC, where rel-
evant we have referenced studies of budesonide/formoterol (Symbicort®; AstraZeneca), International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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another currently available ICS/LABA combination therapy; 
however, the majority of the clinical experience, clinical 
trial data, and other real-world observational outcomes 
data available at this time concern FSC (Advair®/Seretide®; 
GlaxoSmithKline), in part because this formulation has been 
available for a longer period of time.
Impact of exacerbations in COPD
Although there is no consensus on a definition, an exacer-
bation of COPD is generally defined as an acute worsening 
of dyspnea, cough, and/or sputum that is beyond normal 
day-to-day variation and sufficient to warrant a change in 
medication.1,2 Exacerbations are associated with airway 
inflammation that is most often triggered by bacterial or 
viral infection, air pollution or cold weather; no cause is 
identified about one-third of the time.2,12 A bacterial etiol-
ogy, related to either pre-existing lower airway colonization 
or newly acquired bacterial strains, has been identified in 
approximately 50% of exacerbations.13,14 Bacterial load 
has been considered the primary factor; however, a recent 
prospective, longitudinal study utilizing molecular typing 
found that the concentration of either pre-existing or newly 
acquired strains had no or only a small impact on exacerba-
tion incidence, a finding which suggests that more complex 
host-pathogen interactions are involved in exacerbations of 
bacterial etiology than simply bacterial load.13,14
The precise mechanisms underlying the amplified inflam-
matory response remain unclear, but exacerbations have been 
associated with infiltration of neutrophils and eosinophils, 
markers of oxidative stress, into airway walls along with 
tumor necrosis factor-α (TNF-α), leukotriene (LT) B4, 
interleukin (IL)-8, leukotrienes and other pro-inflammatory 
cytokines.2,12,15
Exacerbations are common in COPD and are recognized 
more frequently in patients with more severe disease, some 
of whom are likely to experience three or more exacerbations 
per year.12 Donaldson and colleagues reported a median of 
2.68 exacerbations per year in those with moderate disease 
(GOLD stage II) and 3.43 exacerbations per year in those 
with severe disease (GOLD stage III).16 A history of exacer-
bation in the prior year is predictive of exacerbations in the 
current year.8 Exacerbations tend to cluster together in time; 
Hurst et al found that over a quarter of first exacerbations 
were followed by a second exacerbation within 8 weeks and 
about one-third of all exacerbations were recurrent ones.17 In 
a retrospective cohort study of recently hospitalized patients 
with COPD exacerbations, 13.2% of patients in the refer-
ence group were readmitted within 12 months and 24.3% 
died within the year following a COPD hospitalization.18 
Similarly, a study from Canadian hospitals found that 38% 
of patients admitted for COPD were readmitted within an 
average of 5 months.19
Even with appropriate treatment during the acute episode, 
exacerbations often instigate a downward spiral in which the 
patient never returns to baseline lung or physical functioning 
levels. In a study of 109 patients with COPD, those with fre-
quent exacerbations ($2.92 exacerbations/year) were found 
to experience additional declines of 8.0 mL/year in FEV1 and 
2.22 L/min/year in peak expiratory flow (PEF) compared to 
patients with fewer exacerbations.3 In a longitudinal cohort 
study, only 75% of COPD patients experiencing an exacerba-
tion had regained their basal pulmonary function by 5 weeks 
and 7% had not recovered by 3 months.4 Severe exacerba-
tions requiring hospitalization have even poorer outcomes. 
Inpatient mortality during COPD admission is as high as 
4% to 30%.10 The hospitalization itself is associated with 
functional decline and psychological disorders, including 
anxiety and depression, which contribute to readmission.20–22 
Quality of life, as assessed by the St George’s Respiratory 
Questionnaire (SGRQ) and other health/functional status 
instruments, is also severely impacted by acute exacerba-
tion events, which frequently lead to marked restriction in 
activities of daily living and poorer mental state.5–9 This 
deterioration in physical functioning and health status occurs 
even with no significant deterioration in FEV1, but instead 
correlates with worsened symptoms, particularly dyspnea, 
following exacerbation.6–8 Thus, preventing exacerbations is 
important not only from the short-term clinical perspective, 
but to help patients to function better and feel better in the 
longer term.
From a societal perspective, exacerbations are costly. 
Hospitalizations for exacerbations account for nearly 70% 
of the direct healthcare costs of treating COPD.23 In the 
United States alone, COPD-related hospital inpatient and 
emergency department (ED) costs were estimated to be 
$10 billion in 2003,24 with estimated mean costs in 2001 
of $571 for an emergency department visit, $5997 for a 
standard hospital admission, and $36,743 for an admission 
requiring intensive care and intubation.24,25 Patients with both 
asthma and COPD have particularly high respiratory-related 
and all-cause healthcare costs and use significantly more 
healthcare services than those with asthma or COPD.26–28 
Given the significant clinical, quality of life, and economic 
consequences of exacerbations, their prevention has become 
a widely accepted and singularly important goal in the 
management of COPD.1,2International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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COPD maintenance therapy goals
The primary goals of COPD treatment are to improve 
symptoms and health status and reduce the frequency of 
exacerbations.2 While pharmacologic therapy is needed for 
most patients with COPD, it is just one part of disease man-
agement. Other components of care include regular visits 
to monitor and assess disease progression (including repeat 
spirometry) and identify COPD-related complications and 
co-morbidities, and reducing risk factors such as smoking, 
occupational exposures, and exposure to indoor and outdoor 
air pollution.1,2 Pulmonary rehabilitation and patient educa-
tion can improve health status, help patients cope better with 
symptoms and activities of daily living, and prompt earlier 
recognition of exacerbations by the patient and thus timely 
treatment.2 Pulmonary rehabilitation results in improvements 
in exercise capacity, endurance, walking distance, dyspnea 
and quality of life, and is beneficial even in older patients.29,30 
Smoking cessation education in particular provides a signifi-
cant opportunity to influence the course of the disease and 
reduce age-related decline in FEV1.31 Early identification of 
exacerbations is an important objective of COPD care, as 
early treatment is associated with faster recovery, reduced 
risk for hospitalization, and better quality of life.32
Pharmacologic therapy is based primarily on the patient’s 
symptoms and disease severity, with additional agents added 
as the disease progresses and symptoms worsen. Accord-
ing to guidelines, pharmacotherapy in mild COPD (FEV1/
FVC  0.70 and FEV1  80% of predicted value) focuses 
on short-acting bronchodilators to relieve symptoms, includ-
ing short-acting β2-agonists (eg, albuterol) and short-acting 
anticholinergics (eg, ipratropium bromide, oxitropium); the 
latter have a longer duration of effect (6 to 9 hours) than 
short-acting β2-agonists (4 to 6 hours).1,2 When symptoms are 
persistent, the addition of one or more long-acting broncho-
dilators is recommended (FEV1/FVC  0.70, FEV1  80% 
predicted). Recommended agents include LABAs (eg, 
formoterol, salmeterol), long-acting anticholinergics (eg, 
tiotropium), and, rarely, methylxanthines (eg, theophylline). 
Treatment with a combination of bronchodilators with dif-
ferent durations and mechanisms of action is recommended 
when single-agent therapy is inadequate, as this can achieve 
improved bronchodilation while reducing the risk of side 
effects from a higher dose of a single agent.2 To improve 
health status and reduce the frequency of exacerbations, 
the Global Initiative for Chronic Obstructive Long Disease 
(GOLD) guidelines recommend adding ICS for symptomatic 
patients with GOLD stage III or IV disease, FEV1  50% 
predicted, and repeated exacerbations2, while the American 
Thoracic Society (ATS)/European Respiratory Society (ERS) 
guidelines recommend consideration of ICS for patients 
with FEV1 50% predicted and one or more exacerbations 
in the last year requiring treatment with oral corticosteroids 
or antibiotics.1 The 50% FEV1 cut-off level is somewhat 
arbitrary, and many patients with FEV1  50% have multiple 
exacerbations each year. Clinically, combination therapy 
is often started for patients who are approaching Stage III 
COPD and have frequent exacerbations. Thus, within the 
context of a stepped approach to therapy for COPD, FSC is 
an important option for maintenance therapy and prevention 
of exacerbations.
Treatment goals are unlikely to be reached if the patient 
handles the inhaler device incorrectly and the lungs do 
not receive adequate doses of medication. Teaching the 
patient correct inhaler technique upon initiation of a new 
medication and monitoring the patient’s technique at 
  subsequent visits are crucial but often overlooked tasks.33
Pharmacologic effects
Long-acting β2-adrenoceptor agonists have bronchodi-
lator effects. The LABA salmeterol is highly selective 
for β2-adrenergic receptors and its binding at these sites 
stimulates production of cyclic adenosine monophosphate 
(cAMP), leading to relaxation of bronchial smooth muscle 
and in turn, improved lung emptying during tidal breathing 
and a decreased perception of dyspnea.34–35 Salmeterol also 
has non-bronchodilator effects, including improved muco-
ciliary clearance and ciliary beat activity and inhibition of 
histamine, leukotrienes and other inflammatory mediators 
produced by mast cells.35,36 Its effects on lung function are 
apparent within two hours of administration and last for 
approximately 12 hours.37 A key benefit of salmeterol is thus 
the symptomatic control of COPD on a day-to-day basis and 
a decreased need for rescue medication.34,38
Fluticasone propionate, a synthetic trifluorinated corti-
costeroid, is a glucocorticoid receptor agonist with a receptor 
binding affinity in vitro greater than that of the glucocorticoid 
steroids dexamethasone, beclometasone and budesonide.35 
Glucocorticoid receptors contain DNA-binding proteins that 
alter the transcription rates of responsive genes.39 The anti-
inflammatory effects of fluticasone propionate derive from its 
ability to induce conformational changes in cytoplasmic glu-
cocorticoid receptors that subsequently inhibit the expression 
of inflammatory genes and increase the transcription of anti-
inflammatory genes.35,40 An acute decrease in bronchial blood 
flow occurs following fluticasone propionate administration, 
and although less well understood, may be due to effects on International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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kinases and phosphatases associated with   glucocorticoid 
receptors that lead to rapid changes in cell function and 
vasoconstriction.40 The inflammatory processes in COPD 
primarily involve CD8+ T-lymphocytes (an increase of which 
is associated with increased airflow obstruction), CD68+ mac-
rophages, and infiltration of neutrophils into airway and lung 
parenchyma.41,42 Some research indicates that fluticasone pro-
pionate does not reduce the number of CD8 cells in bronchial 
epithelium, but reduces the CD8:CD4 ratio, suggesting that it 
prevents a rise in CD4 cells.43 It also has been shown to reduce 
bronchial mucosal mast cells,43,44 neutrophils,45 and systemic 
markers of inflammation, including C-reactive protein, RP, 
IL-6, and other inflammatory cytokines.46
Pharmacologic effects of co-administration 
of fluticasone propionate and salmeterol
There is evidence that the co-administration of fluticasone 
propionate and salmeterol has synergistic effects at the 
molecular level whereby fluticasone propionate enhances 
the β-agonist effect of salmeterol and salmeterol enhances 
the anti-inflammatory effects of fluticasone propionate.40,41 
Several mechanisms appear to be involved. Glucocorticoids 
prevent the down-regulation of β2-adrenoceptors and increase 
β2-adrenoceptor gene transcription; this leads to increased 
β2-adrenoceptor synthesis, providing additional receptors 
for β2-agonists to activate and increasing intracellular cAMP 
levels.40,41,47 Long-acting β2-agonists may improve the anti-
inflammatory effects of ICS by facilitating translocation of 
the glucocorticoid receptor/ligand complex into the nucleus.35 
Adding salmeterol to fluticasone propionate leads to a greater 
reduction in TNF-α and macrophage chemokines following 
rhinovirus infection than is achieved by ICS therapy alone.48,49 
These examples of synergistic molecular effects of salmeterol 
and fluticasone propionate are consistent with results of in vivo 
studies and clinical trials that have observed greater clinical 
efficacy with FSC than with its individual components.36,50–54 
In contrast, a bronchial biopsy study of steroid-naïve current 
and former smokers with moderate to severe COPD found that 
fluticasone propionate 500 µg reduced CD3+, CD4+, CD8+, 
mast cells and hyperresponsiveness at 6 months compared to 
placebo, but adding LABA (50 µg) did not lead to greater anti-
inflammatory effects.55 Sample size in this study was small 
(N = 114), however, and a larger follow-up study is needed.
Clinical efficacy
Compared to monotherapy with fluticasone propionate or 
salmeterol, FSC has been shown in a number of clinical tri-
als to lead to improvements in one or more of the   following 
parameters: lung function, exacerbation rates, dyspnea, 
chronic bronchitis symptoms, night awakenings, frequency of 
rescue medication use and health status.36,42,47,51–54 In review-
ing clinical efficacy, we have relied primarily on level I 
evidence from randomized controlled trials (RCTs).
Lung function and symptoms
The comparative effects of FSC on lung function and symp-
toms versus fluticasone propionate or salmeterol monotherapy 
have been investigated in several RCTs of COPD (Table 1). 
In a 24-week trial of 691 patients, Mahler et al reported a 
significantly greater increase in pre-bronchodilator FEV1 with 
FSC (500/50 µg) than with salmeterol (50 µg), resulting in an 
improvement of 14.5% over baseline, and a greater increase 
in 2-hour post-bronchodilator FEV1 with FSC than with 
fluticasone propionate (500 µg).52 Patients receiving FSC also 
had improved morning PEF and less dyspnea than patients who 
received fluticasone propionate or salmeterol alone. Evidence 
of a synergistic effect of combination therapy was seen, as 
the PEF mean change from baseline was greater than the 
sum of the changes achieved with fluticasone propionate and 
salmeterol individually. Similarly, a 12-month trial (N = 1465) 
observed greater improvements in pre- and post-  bronchodilator 
FEV1, health status, cough, and breathlessness with FSC 
500/50 µg compared with either fluticasone propionate 500 
µg or salmeterol 50 µg, and night-time awakenings were 
decreased with either FSC or fluticasone propionate compared 
to salmeterol.50 In these trials, an FSC dosage of 500/50 µg 
administered twice daily was used. The effects of a lower dose 
of FSC on lung function were assessed in a randomized con-
trolled trial of 723 patients.36 Hanania and colleagues reported 
a greater increase in morning predose FEV1 with FSC 250/50 
µg than with either fluticasone propionate 250 µg or salmeterol 
50 µg, with effects observable within 24 hours of the first dose 
and sustained over 24 weeks, and an increased 2-hour postdose 
FEV1 with FSC compared with salmeterol.
The effect of FSC on the rate of decline in lung function 
(FEV1) was evaluated as a secondary outcome in the Towards 
a Revolution in COPD Health (TORCH) trial, a 3-year, ran-
domized, controlled trial of 6112 patients with moderate-to-
severe COPD.56 Lung function (FEV1) declined more slowly 
with FSC 500/50 µg treatment (39 mL/year) compared to 
placebo (55 ml/year); however, this rate of decline was not 
significantly different from the rates of decline seen in the 
fluticasone propionate 500 µg (42 mL/year) and salmeterol 
50 µg (42 mL/year) treatment arms. Two recent parallel-
group trials of FSC 250/50 µg and salmeterol 50 µg evaluated 
morning predose FEV1 as a secondary endpoint and observed International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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declines in lung function in both groups over the 52-week 
treatment period, but FSC treatment preserved lung function 
better than did salmeterol alone.51,53 Moreover, withdrawal of 
fluticasone propionate in patients receiving FSC (500/50 µg) 
has been shown to result in deterioration in lung function and 
dyspnea and an increase in mild exacerbations.57
exacerbation prevention
There is little evidence that LABA alone is effective in pre-
venting exacerbations, but clinical trials have shown that ICS 
alone (fluticasone propionate or budesonide) reduces COPD 
exacerbations in the range of 10% to 20%.50,58–61 Several 
RCTs also have shown that combination ICS/LABA therapy 
is superior to LABA or ICS alone in reducing exacerbations 
(Table 2).42,51,53,54,62 In contrast, a 12-month trial (N = 1465) found 
no difference in exacerbation rates between FSC 500/50 µg, 
salmeterol 50 µg or fluticasone propionate 500 µg.50
In the 3-year TORCH study, FSC 500/50 µg reduced 
moderate/severe exacerbations by 12% compared to sal-
meterol, 9% compared to fluticasone propionate, and 25% 
compared to placebo.50 A shorter 44-week trial of 994 COPD 
patients randomized to FSC 500/50 µg or salmeterol 50 µg 
reported 35% fewer exacerbations in the FSC group.42 Most 
recently, 2 replicate parallel-group trials evaluated whether 
the FSC 250/50 µg dose is also associated with reducing 
annual rates of moderate or severe COPD exacerbations 
(Figure 1).51,53 These studies observed reductions in moderate/
severe exacerbations of 30.4% and 30.5%, respectively, with 
FSC compared to active treatment with salmeterol 50 µg.
Similar findings have been observed for budesonide/
formoterol (160/4.5 µg). In a 12-month trial, this combina-
tion therapy led to a 35% lower rate of mild exacerbations 
compared to budesonide 200 µg alone.62 The same study 
observed a 23% lower rate of severe exacerbations with 
Table 1 Clinical trials of the effect of fluticasone propionate/salmeterol combination therapy on lung function, symptoms and health 
status
Study  No. of patients  
(duration)
Treatment  
comparisons
Major findings: lung  
function
Major findings: health  
status and symptoms 
Calverley et al 200350 1465 (52 weeks) Twice daily FSC 500/50 µg  
vs FP 500 µg, SAL 50 µg, or  
placebo
Fev1 increased with FSC  
compared to FP, SAL and  
placebo
Health status score (SGRQ) was improved  
with FSC at week 8 (-4.3, SD 10.8) and  
52 (-4.5, SD 12.9) compared to placebo  
and FP 
Dyspnea and use of relief medication  
improved with FSC compared to placebo, FP   
and SAL. Night-time awakenings decreased  
with FSC compared to placebo and SAL
Mahler et al 200252  691 (24 weeks) Twice daily FSC 500/50 µg  
vs FP 500 µg, SAL 50 µg,  
or placebo
Pre-dose Fev1 increased with  
FSC compared to SAL and  
placebo; 2-hour post-dose  
Fev1 increased with FSC  
compared to FP and placebo;  
dyspnea score improved with  
FSC compared to FP and  
placebo
Health status improved with FSC (CDRQ,  
10.0) compared to placebo (5.0) and FP  
(4.8), but not compared to SAL (8.0)  
Dyspnea and use of relief medication  
improved with FSC compared to SAL,  
FP and placebo. Night-time awakenings  
decreased with FSC compared to SAL and  
placebo
Hanania et al 200336  723 (24 weeks) Twice daily FSC 250/50 µg  
vs FP 250 µg, SAL 50 µg,  
or placebo
Morning pre-dose Fev1  
increased with FSC compared  
to SAL and placebo; 2-hour  
post-dose Fev1 increased with  
FSC compared to FP and  
placebo
Health status improved with FSC compared  
to placebo (CDRQ, +5.2) but not compared   
to FP or SAL 
Dyspnea improved with FSC  
and SAL compared to placebo. Use of  
rescue medication decreased with FSC  
compared to placebo and FP. Night-time  
awakenings decreased with FSC compared  
to placebo and SAL
Celli et al 200856  5343 (3 years) Twice daily FSC 500/50 µg  
vs FP 500 µg, SAL 50 µg,  
or placebo
The rate of decline in Fev1  
was reduced with FSC, FP and  
SAL compared to placebo;  
greatest reduction was with  
FSC compared to placebo;  
differences between treatment  
arms were not significant 
Not assessed
Abbreviations: CRDQ, chronic respiratory disease questionnaire; FP, fluticasone propionate; FSC, fluticasone propionate/salmeterol combination; SAL, salmeterol; SGTQ, 
St George’s respiratory questionnaire; TDI, transition dyspnea index.International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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budesonide/formoterol compared to formoterol (4.5 µg) but 
no difference compared to budesonide.
Improvement in exacerbation rates in patients treated 
with FSC has been most evident in patients with more severe 
disease; however, a recent analysis of the TORCH trial data 
based on disease severity found that FSC treatment decreased 
exacerbations by 31% relative to placebo in patients with 
GOLD stage II COPD (moderate; FEV1/FVC  0.70, 
50%  FEV1  80% predicted).63
Survival
It is not entirely clear whether or not FSC treatment confers a 
survival benefit, as clinical studies to date have been underpow-
ered to assess mortality. The TORCH study reported a 17.5% 
lower risk for death (2.6% absolute risk reduction) in the com-
bination therapy group; however, this finding was just short 
of statistical significance (P = 0.052).54 Statistical and clinical 
significance are not always the same and the observed absolute 
reduction in risk identified in the TORCH trial deserves care-
ful clinical consideration. Practitioners of clinical medicine 
may feel less concern with a small deviation from a statisti-
cally significant finding when the absolute size of the effect 
is relatively large and clinically relevant, as sample size has a 
large influence on the P-value.64 In a pooled analysis of seven 
randomized controlled trials, Sin and colleagues observed a 
decrease in all-cause mortality of approximately 27% with ICS 
plus LABA compared to placebo (hazard ratio [HR] 0.73, 95% 
confidence interval [CI], 0.55 to 0.96).65 In several retrospec-
tive observational studies, FSC or ICS have been associated 
with significantly lower mortality,18,66–69 but one other study 
found no survival benefit associated with ICS.70
Health status and quality of life
Measures of lung function, such as FEV1, do not necessarily 
reflect the degree of disability experienced by patients with 
COPD.6,8 While patients may not experience a decline in 
FEV1 over a particular period of time, they may find none-
theless that it has become harder to walk to the mailbox, 
a sign of decreased functional capability. One of the hurdles 
to gleaning associations between clinical measures and 
patient-reported outcomes is the lack of congruence between 
accepted lung function measures and measures important to 
patient well-being and quality of life. Assessment of health 
status and quality of life improves our understanding of the 
effects of treatment and the impact of exacerbations.
Exacerbations produce a short-term deterioration in 
COPD-specific health status and dyspnea, with significant 
improvement generally following within 10 days.71 Seemun-
gal followed patients for 1 year and showed that those with 
more exacerbations had significantly worse health-related 
quality of life (HRQOL) as measured by the SGRQ.8 In 
addition, dyspnea was not related to exacerbation frequency 
but was strongly related to HRQOL, indicating the very 
real effect of symptoms on health status independent of 
Table  2  Clinical  trials  of  efficacy  of  fluticasone  propionate/salmeterol  combination  therapy  in  the  prevention  of  COPD 
exacerbations
Study  No. of patients  
(duration)
Treatment  
comparisons
Primary outcome  
measure
Major findings
Calverley et al 200754  6112 (3 years) Twice daily FSC 500/50 µg  
vs FP 500 µg, SAL 50 µg, or  
placebo
All cause mortality;  
exacerbations
Rate of moderate/severe exacerbations was  
12% lower with FSC compared to SAL; 9%  
lower with FSC compared to FP
Rate of exacerbations requiring oral 
corticosteroids was 13% lower with FSC 
compared to FP; 29% lower with FSC 
compared to SAL 
Differences in all-cause mortality between 
groups were not significant
Kardos et al 200742  994 (44 weeks) Twice daily FSC 500/50 µg  
vs SAL 50 µg
exacerbations Rate of moderate/severe exacerbations was   
35% lower with FSC compared to SAL 
Anzueto et al 200953  797 (52 weeks) Twice daily FSC 250/50 µg  
vs SAL 50 µg
exacerbations  Rate of moderate/severe exacerbations was   
30.4% lower with FSC compared to SAL 
Rate of exacerbations requiring systemic  
corticosteroids was 40% lower with FSC  
compared to SAL
Ferguson et al 200851  782 (52 weeks) Twice daily FSC 250/50 µg  
vs SAL 50 µg
exacerbations Rate of moderate/severe exacerbations was  
30.5% lower with FSC compared to SAL 
Rate of exacerbations requiring systemic  
corticosteroids was 40% lower with FSC  
compared to SAL
Abbreviations: FP, fluticasone propionate; FSC, fluticasone propionate/salmeterol combination; NS, not statistically significant; SAL, salmeterol.International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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Figure 1 (A) Reprinted with permission from Anzueto A, Ferguson GT, Feldman G, Chinksy K, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD 
exacerbations and impact on patient outcomes. COPD. 2009;6(5):320–329.53 Copyright © 2009 Taylor & Francis. (B) Reprinted with permission from Ferguson GT, Anzueto A, 
Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 µg) or salmeterol (50 µg) on COPD exacerbations. Respir Med. 2008;102(8): 
1099–1108.51 Copyright © 2008 elsevier.
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  measurable changes in lung function. In a 2-year study of 
patients with moderate COPD (GOLD stage II), those with 
3 or more exacerbations had SGRQ scores that were approxi-
mately 2 points higher (indicating worse quality of life) per 
year than patients with fewer exacerbations, and the biggest 
changes were associated with the symptom subscale.6 Hos-
pital admissions were also associated with a higher SGRQ 
score, and it was noted that patients with frequent exacer-
bations during follow-up had significantly lower HRQOL 
at baseline, suggesting that these patients were already at 
increased risk for exacerbation.
Treatment with FSC has resulted in clinically important 
improvements in health status (Table 1). In a 24-week study 
of 691 patients, the FSC group had a significant increase 
(improvement) from baseline in mean Chronic Respiratory 
Disease Questionnaire (CRDQ) score compared to the flutica-
sone propionate and placebo groups (a change of 10.0 points 
from baseline for FSC versus 4.8 for fluticasone propionate and 
5.0 for placebo).52 In 2 parallel 12-month clinical trials, night-
time awakenings were decreased by approximately 1 awaken-
ing per week in the FSC groups, while awakenings increased 
slightly in the salmeterol groups.51,53 Symptoms and health International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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status in COPD patients generally worsen over time, but the 
FSC groups in both trials had better dyspnea and SGRQ scores 
compared to baseline than the salmeterol groups, although the 
changes in SGRQ scores did not reach the threshold of 4 units 
considered clinically meaningful. Other trials also have shown 
improvements in symptoms (generally dyspnea or cough) and 
HRQOL in patients treated with FSC.36,42,47,50,54,72
Pharmacoeconomic evidence
While randomized clinical trials are important for their strong 
internal validity in interventional research, they are expensive 
to conduct and lack generalizability due to restrictive patient 
inclusion criteria. Observational, real-world studies using 
administrative claims data are an additional way to answer 
research questions. These have greater external validity and 
can be designed so as to reduce selection bias in the absence 
of randomization. In this section, we describe studies that 
have examined clinical and economic outcomes using obser-
vational, retrospective designs.
The direct costs of medical care for COPD patients are 
approximately double those for patients without COPD, 
and reducing exacerbations could significantly lower the 
economic burden of the disease.73 Retrospective analyses of 
healthcare claims data suggest that sizable cost savings might 
be achieved with FSC therapy, primarily through prevention 
of exacerbation-related hospitalizations.
A study using data from the UK General Practice 
Database found patients prescribed ICS and LABA had a 
38% lower risk for a combined endpoint of hospitalization 
or death than patients prescribed ICS plus a short-acting 
beta-agonist (HR 0.62; 95% CI, 0.43 to 0.87).74 Similarly 
Soriano and colleagues reported that patients discharged 
with ICS and LABA had a 41% lower risk for rehos-
pitalization or death in the following year compared to 
patients discharged with a short-acting beta-agonist.18 In 
the TORCH trial, however, annual hospital admission rates 
for exacerbations were similar in the FSC and salmeterol 
groups, but were 17% and 18% lower, respectively, than 
in the placebo group.54
Cost analyses comparing FSC to ipratropium (alone or 
in combination with albuterol) show cost benefits as well. 
Among managed care enrollees, those prescribed ICS plus 
LABA had a 47% lower risk for a COPD hospitalization (HR 
0.533, 95% CI, 0.328 to 0.865) and a 36% lower risk for any 
respiratory admission compared to ipratropium therapy (HR 
0.643; 95% CI, 0.512 to 0.808).75 Newly diagnosed COPD 
patients receiving initial maintenance therapy with FSC 
had a 32% lower risk for hospitalization/ED visit during the 
first 6 months of therapy compared with patients receiving 
ipratropium therapy (HR 0.685, 95% CI, 0.620 to 0.757), 
and a lower risk than patients receiving either fluticasone 
propionate or salmeterol.76 Two US studies, one in a Texas 
Medicaid population and one in a cohort of Medicare-eligible 
health plan members, reported 27% and 45% reductions in 
risk, respectively, for a COPD-related hospitalization or ED 
visit with FSC compared to ipratropium.73,77 In addition, 
these analyses found lower overall medical costs for FSC 
therapy even though FSC was associated with higher phar-
macy costs than was ipratropium. A third study, however, 
found no difference in COPD-related costs between FSC 
and ipratropium.78
Prescribing considerations
In the United States, 250/50 µg FSC is approved for twice-
daily maintenance therapy in COPD to improve lung func-
tion and reduce exacerbations.79 In Europe, the approved 
dose is 500/50 µg and its use in patients with milder 
COPD (FEV1  60% of predicted pre-bronchodilator 
value and a history of exacerbations) has been approved 
based primarily on the TORCH study, which found that 
FSC is associated with a reduced rate of exacerbations, 
improved lung function and HRQOL, and possibly 
improved survival.34,54,56
Current evidence-based guidelines recommend the 
addition of inhaled corticosteroid (ICS) for symptomatic 
patients with moderate-to-severe disease (FEV1  50% 
predicted) and repeated exacerbations.1,2 It is suggested that 
a dose sufficient in strength to establish control be chosen, 
followed by a dose reduction, when appropriate, to a level 
that maintains control and minimizes deleterious effects. 
Although 3 exacerbations in 3 years is suggested as a thresh-
old for considering more aggressive therapy, as with other 
illnesses, good judgment must be exercised in the clinical 
setting. How is one to treat a patient with FEV1  50% pre-
dicted and 2 exacerbations in the past year, or 1 very severe 
exacerbation? Another issue clinicians must consider is the 
prevention of repeat exacerbations. Should one start patients 
on FSC sooner, given the clinical evidence for its efficacy 
and safety in COPD? Or add FSC to other long-acting bron-
chodilators to slow, if not prevent, the inevitable progression 
of COPD? A weighing of the risks and benefits, including 
consideration of the patient’s symptoms and functional sta-
tus, is especially necessary in treating patients with mild or 
moderate COPD.International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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Safety
Treatment with ICS/LABA is generally well tolerated. 
In most clinical trials, there has been good medication 
  adherence and a lower withdrawal rate due to adverse 
events in the FSC group compared to the placebo and/
or salmeterol groups.42,50–53,56 Oral candidiasis is the most 
frequent adverse event associated with ICS use. In a recent 
post hoc safety analysis of TORCH trial data, no significant 
differences in bone density were seen between the groups 
receiving study drugs and the placebo group.80 An increased 
risk of pneumonia has been associated with FSC use. In the 
largest and longest study to date, the three-year TORCH 
trial, a higher incidence of pneumonia was seen in the FSC 
(19.6%) and fluticasone propionate (18.3%) groups than 
in the salmeterol (13.3%) and placebo (12.3%) groups (all 
P  0.001).54 However, there was not a corollary increase 
in pneumonia-related hospitalizations or deaths in the 
FSC group. The decrease in the exacerbation rate (-0.28 
events/100 patients/year) was greater than the increase in 
pneumonia (+0.03 events/100 patients/year). A more recent 
post-hoc analysis of TORCH data reported 88 pneumonia 
events per 1000 treatment-years for FSC and 84 events per 
1000 treatment-years for fluticasone propionate, compared 
with 52 events per 1000 treatment-years with salmeterol or 
placebo.81 Factors associated with increased risk for pneu-
monia included age $55 years, FEV1  50% predicted, 
COPD exacerbation in the prior year, a worse dyspnea score 
and body mass index 25 kg/m2. In addition, a 44-week 
trial comparing FSC to salmeterol reported that a greater 
incidence of pneumonia was associated with FSC use (4.5% 
vs 1.8%).42 The INSPIRE study, a trial of the effects of FSC 
versus tiotropium on exacerbation rates, found equivalent 
exacerbation outcomes, but a higher incidence of pneumonia 
in the FSC group (8% vs 4%; P  0.01); however, overall 
mortality was significantly lower in the FSC group.82 The 
pneumonia data from some trials have been difficult to 
interpret because pneumonia events were not anticipated 
when the studies began and so the study protocols did 
not require that diagnosis be confirmed by chest X-ray. 
Interestingly, a recent meta-analysis of seven large clinical 
trials found no differences in pneumonia between patients 
receiving the ICS budesonide (with or without formoterol) 
and patients receiving other therapy; pneumonia occurred in 
3% of patients in each group.83 Nevertheless, the possibility 
of a slightly increased risk of pneumonia with ICS or FSC 
therapy, especially in patients at increased risk for respira-
tory infection, warrants vigilance.
Multiple morbidities
Patients seldom present only with COPD. Many patients 
have multiple morbidities including asthma, cardiovascular 
disease, hypercholesterolemia, hypertension, depression, 
cataracts, osteoporosis and diabetes (Figure 2).84 Many of 
these conditions are linked by common risk factors, most 
notably smoking, and COPD and cardiovascular disease 
are particularly closely related. Comorbid conditions may 
account for some of the deterioration in lung health seen in 
COPD and should be assessed and treated.85 Many patients 
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Figure 2 estimated prevalence of hospital discharges with selected comorbidities in patients with and without COPD.
Notes: Bars represent the age-adjusted percentage with Se bars. Black bars show patients with COPD (either as primary or secondary discharge diagnosis). white bars show 
patients without any mention of a COPD discharge diagnosis. The prevalence of all listed comorbidities is different across COPD categories (P < 0.01).
Abbreviations: IHD, ischemic heart disease; CHF, congestive heart failure; RF, respiratory failure; PvD, pulmonary vascular disease; TM, thoracic malignancy. 
Reprinted with permission from Holguin F, Folch e, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. 
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with COPD are nutritionally depleted, and malnutrition is 
associated with poor prognosis; dietary counseling and nutri-
tional support have been shown to improve airflow and 
quality of life.86,87 In the presence of multiple morbidities and 
comorbid conditions, treatment decisions must be based on 
the various risks and benefits relative to all of the patient’s 
health problems.80,85,88 Therapy for one condition, however, 
may be contraindicated in the presence of a second morbid-
ity, complicating treatment decisions.
Given the high prevalence of osteoporosis in patients 
with COPD, concern has been raised about the long-term 
effects of ICS on bone density. A recent analysis of data 
from the TORCH trial found that 18% of men and 30% 
of women had osteoporosis and 42% of men and 41% of 
women had low bone density at baseline.80 However, no 
significant changes in bone mineral density were observed 
in any of the treatment arms (FSC, fluticasone propionate, 
salmeterol, placebo) during 3 years of follow-up. Rates of 
fractures across treatment groups were also low, with no 
differences detected between groups. Smoking, lack of 
calcium and vitamin D, and a sedentary lifestyle contribute 
significantly to low bone density, and these areas present 
opportunities for lowering osteoporosis risk in patients with 
COPD. Therapy for COPD with ICS should not necessarily 
be ruled out in the case of a patient with low bone density, 
as more aggressive therapy might improve functional 
status enough to permit a patient to be more active, not 
only reducing osteoporosis risk but impacting favorably 
on the course of COPD and other morbidities, such as 
hypertension and cardiovascular disease. With appropri-
ate pharmacotherapy, a patient might also be better able to 
participate in pulmonary rehabilitation, an intervention that 
may not only improve physical functioning and symptom 
management, but reduce depression, a common problem in 
patients with COPD.89–91
There has also been concern that ICS therapy in COPD 
patients with diabetes may make glycemic control more 
difficult. However, a small study (N = 12) of the effect of 
ICS on glucose control in patients with COPD and diabetes 
found no significant change in hemoglobin A1c over 6 weeks 
of therapy.92 It appears prudent to carefully monitor patients 
for changes in glycemic control following ICS or FSC 
therapy.
Adherence issues
Finally, in making therapy decisions, treatment acceptance 
and adherence to treatment must be considered, since no 
medication regimen is effective if the medication is not 
taken. Increased adherence to COPD inhaled therapy is 
associated with improved mortality and reduced hospital-
ization.93 Patient adherence to treatment regimens in COPD 
is not optimal and treatment persistence is generally low for 
inhaled medications.94,95 Poor adherence can be related to 
overuse, underuse, or improper use of a medicine, and any of 
these problems may be sporadic or systematic, intentional or 
unintentional.94 Unintentional non-adherence is particularly 
an issue with inhaled medication; one study reported that 
only 43% of patients used a metered-dose inhaler (MDI) 
correctly, 55% used an MDI plus spacer correctly, and 
59% used a dry powder inhaler correctly.96 Patients make 
mistakes even directly following face-to-face instruction, 
underscoring the importance of physician’s attentiveness 
to patients’ inhaler technique.95 As a routine part of office 
visits, adherence needs to be assessed in a neutral man-
ner and addressed collaboratively to improve therapeutic 
outcomes.
The feasibility of using combination ICS/LABA therapy 
has improved with the availability of single inhaler devices 
that contain both medications, and this may also improve 
patient adherence, in part because salmeterol provides 
symptom relief, making it more likely that patients will 
comply with scheduled dosing regimens.97 In a 12-month 
period, patients with COPD who were prescribed FSC 
obtained more refills than patients prescribed salmeterol or 
ICS76 and in a second study of pharmacy claims, medication 
compliance was 12% higher with FSC than with ipratro-
pium.78 Thus, when both ICS and LABA are needed, FSC 
delivered via a single inhaler may result in better treatment 
adherence.94,97
Just as important as optimizing patient adherence to 
pharmacotherapy is the need to bridge the existing gap 
between optimal management of COPD and actual practice. 
An existing hurdle to overcome is the frequent failure to 
recognize that smoker’s cough and bronchitis are in reality 
COPD and exacerbations of COPD.98 Simply put, if clinicians 
do not correctly identify the patient’s condition as COPD, 
there is little chance the disease will be treated according to 
existing guidelines for care. Use of a simple questionnaire 
may be beneficial for screening for COPD in primary care 
patients.98,99 In addition, increased awareness that the course 
of COPD and patient’s quality of life can be significantly 
improved by newer maintenance therapies and patient self-
management education is needed. Undertreatment of COPD 
is common and being recognized.88 A study of Canadian 
patients with COPD found that 33% had never received a 
written action plan and 67% had not been told how to prevent International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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Dovepress
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an   exacerbation.100 Several concerns about potential side 
effects with ICS have been allayed by new research, and there 
is a need to educate physicians about the benefits and risks 
of COPD maintenance therapies, including treatment with 
FSC, as well as the need for vigilance regarding untoward 
effects. Other barriers to optimal care, such as formulary 
decisions that limit the clinician’s ability to do what is best 
for the patient, will require health policy changes.
Lessons for the future
In appropriate patients, FSC is an effective therapy option 
that has been shown to reduce the frequency of exacerbations 
in patients with COPD, modestly improve lung function, and 
improve dyspnea, health status and quality of life. A range of 
studies suggests that fluticasone propionate and salmeterol 
have synergistic effects when administered together that 
improve their efficacy in controlling symptoms and reduc-
ing exacerbations. While clinical trials have clearly shown a 
benefit of FSC in preventing exacerbations in Stage III and IV 
COPD, there is also some evidence of benefit in patients with 
moderate COPD, and this topic warrants further research. 
Investigations of the optimal doses of FSC and comparative 
studies of the clinical and pharmacoeconomic benefits of 
FSC relative to other medications for COPD maintenance 
therapy are also needed. In particular, additional studies to 
clarify the potential value of triple therapy with FSC and 
tiotropium would be beneficial, and research in this area is 
underway.
For both the clinician and patient, the optimal scenario 
would be to have available a range of therapeutic options 
that meet the needs of patients with differing symptoms, 
lung function profiles, and comorbidities, that improve 
quality of life, and that minimize adherence issues and del-
eterious effects. Treatment with FSC within the context of 
COPD maintenance therapy is a useful, effective option in 
the clinician’s armamentarium, which based on evidence to 
date appears to have benefits for disease management, cost, 
adherence, and quality of life.
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